Difference between revisions of "Team:TECHNION-ISRAEL/Model"

 
(27 intermediate revisions by 4 users not shown)
Line 7: Line 7:
 
 
 
<meta charset="utf-8">
 
<meta charset="utf-8">
−
+
<meta name="viewport" content="width=device-width, initial-scale=1">
−
+
−
+
<script>
−
+
window.addEventListener("hashchange", function() { scrollBy(0, -130) })
−
<script>
+
</script>
 +
 +
<script>
  
−
//up arrow:
+
//up arrow:
−
$(document).ready(function(){
+
$(document).ready(function(){
−
$(window).scroll(function () {
+
$(window).scroll(function () {
−
if ($(this).scrollTop() > 350) {
+
if ($(this).scrollTop() > 350) {
−
$('#back-to-top').fadeIn();
+
$('#back-to-top').fadeIn();
−
} else {
+
} else {
−
$('#back-to-top').fadeOut();
+
$('#back-to-top').fadeOut();
−
}
+
}
−
});
+
});
−
// scroll body to 0px on click
+
// scroll body to 0px on click
−
$('#back-to-top').click(function () {
+
$('#back-to-top').click(function () {
−
$('#back-to-top').tooltip('hide');
+
$('#back-to-top').tooltip('hide');
−
$('body,html').animate({
+
$('body,html').animate({
−
scrollTop: 0
+
scrollTop: 0
−
}, 800);
+
}, 800);
−
return false;
+
return false;
−
});
+
});
−
+
−
$('#back-to-top').tooltip('show');
+
$('#back-to-top').tooltip('show');
  
−
});
+
 +
 +
});
  
−
</script>
+
</script>
 +
<style>
 +
.bottom-column
 +
{
 +
    float: none;
 +
    display: table-cell;
 +
    vertical-align: bottom;
 +
}
 +
</style>
 
 
−
<style>
 
 
 
−
ul {
 
−
list-style-image: none;}
 
−
 
−
 
−
.model-list {
 
−
line-height:35px;
 
−
font-size: 18px;
 
−
}
 
−
 
−
.model-ul {
 
−
line-height:35px;
 
−
font-size: 18px;
 
−
list-style-type: circle;
 
−
}
 
−
 
−
.model-ul>li {
 
−
list-style-type: inherit;
 
−
}
 
−
 
−
.inner-model>li {
 
−
list-style-type: inherit;
 
−
}
 
−
.inner-model {
 
−
line-height:35px;
 
−
font-size: 18px;
 
−
list-style-type: disc;
 
−
}
 
−
 
−
.modelimg {
 
−
border-radius:25px ;
 
−
width: 100%;
 
−
margin:auto;
 
−
display:block;
 
−
}
 
−
 
−
.collar{
 
−
  float: right;
 
−
  width: 30%;
 
−
  margin-left: 40px;
 
−
  margin-bottom: 10px;
 
−
  border-radius:25px
 
−
  }
 
−
</style>
 
 
</head>
 
</head>
 
 
Line 87: Line 55:
 
<br>
 
<br>
 
<div class = "container-fluid">
 
<div class = "container-fluid">
−
<div class= "row">
+
 
<h1> Model </h1>
 
<h1> Model </h1>
−
 
−
<img src="https://static.igem.org/mediawiki/2017/a/af/T--TECHNION-ISRAEL--co-model.png" class="cover" alt=""  style= "width:18% ; margin: auto;">
 
 
<br>
 
<br>
 +
<img src="https://static.igem.org/mediawiki/2017/7/75/T--TECHNION-ISRAEL--model_header.png" class="cover" alt=""  style= "width:18% ; margin: auto;">
 
<br>
 
<br>
−
+
<br>
 +
<br>
 +
<div class= "row">
 
<div class =  "col-md-offset-2 col-md-8" >
 
<div class =  "col-md-offset-2 col-md-8" >
−
+
<div class= "row">
−
<br>
+
<div class =  "col-md-12" ><p>
−
<div class= "row">
+
Modelling is an important part of any project within iGEM. As part of our project, we decided to model two separate systems: We created a kinetic model for the Tolerance Assay Model, and collaborated with team Edinburgh UG in order to model a potential “Kill Switch.”
−
<div class =  "col-md-12" >
+
−
<div class = "wrapper">
+
−
<h3> CRE Model – Team SMORE </h3>
+
−
<p>
+
−
In the early stages of our project, before we decided to proceed with our final “<a href ="https://2017.igem.org/Team:TECHNION-ISRAEL/kill_switch">kill Switch</a>” design, we had considered using Cre recombinases in order to disable our genetic circuit. We designed our plasmid and flanked it with two Lox-P sites, so that once Cre recombinases were introduced into the cell, it would excise the gene that was flanked between these two Lox-P sites (see figure 1).
+
−
</p>
+
−
+
−
<img src ="https://static.igem.org/mediawiki/2017/d/d8/T--TECHNION-ISRAEL--CRElox.png" alt="" class="collar">
+
−
</div>
+
−
</div>
+
−
</div>
+
−
+
 
<br>
 
<br>
−
<div class= "row">
+
Each of these models provided us with important information that directly impacted our general design and our wet-lab experiments.
−
<div class =  "col-md-12" >
+
−
<p>
+
−
In order to examine whether using recombinases was a viable option for our system we understood that modelling the mechanism was crucial. Unfortunately, such a model is extremely complex, and for lack of time and experience, was not feasible for us to Create. Luckily, we discovered that Team SMORE, whose whole project was concerned with recombinases, had already created such a model. Team SMORE generously offered to help us model our system, and through intense collaboration and specific modifications to their original model, we managed to attain informative results that shaped our decision regarding which “kill switch” mechanism to use.
+
 
</p>
 
</p>
−
+
 
−
<br>
+
</div>
−
<p>
+
</div>
−
We modelled two different processes:
+
−
</p>
+
<div class="row">
−
<ol class= "model-list">
+
<br>
−
<li> Cells transiently transfected with our ToloGen plasmid, assuming a copy number of 20 </li>
+
<div class="col-md-12">
−
<li> Cells with stable integration of out ToloGen construct, this means a copy number of 1 </li>
+
<img class="no-rad" src="https://static.igem.org/mediawiki/2017/e/ed/T--TECHNION-ISRAEL--motekush.png" alt = "" style= "width: 125px; float:right;">
−
</ol>
+
</div>
−
+
</div>
−
<p>
+
<br>
−
This allowed us to analyze how the Cre system would function in our lab as well as in future <i>in-vivo</i> applications.
+
<div class="row ">
−
</p>
+
<div class =  "col-md-offset-1 col-md-10" >
−
<br>
+
<div class="row ">
−
<p>
+
<div class="col-md-offset-2 col-md-3 bottom-column">
−
Lastly, we analyzed two Cre delivery systems:
+
<a href="https://2017.igem.org/Team:TECHNION-ISRAEL/Assay_Model">
−
</p>
+
<img src="https://static.igem.org/mediawiki/2017/6/6d/T--TECHNION-ISRAEL--model_intro_2.png" class="no-rad" alt=""  style= "width: 65%; margin: auto;">
−
+
</a>
−
<ol class= "model-list">
+
</div>
−
<li> Where Cre enzyme is taken into the cell directly through endocytosis  </li>
+
−
<li> Where a Cre enzyme producing plasmid is taken into the cell </li>
+
−
</ol>
+
−
<br>
+
−
<p>
+
−
Assumptions:
+
−
</p>
+
−
+
−
<ol class= "model-list">
+
−
<li> Homogeneous mixture assumed throughout (e.g. if Cre molecule number is set to 100 at time = 0, it is assumed that the 100 Cre molecules are dispersed evenly inside the compartment regardless of its delivery method) </li>
+
−
<li> Values for half-life are taken from ‘general’ proteins </li>
+
−
<li> Compartmentalization is not taken into account (i.e. ignored nuclear export and import rate & spatio-temporal separation of transcription and translation, if any)</li>
+
−
</ol>
+
−
<br>
+
−
<p>
+
−
Simulation Settings:
+
−
</p>
+
−
+
−
<ul class= "model-ul">
+
−
<li>mRNA half-life (if using): 2 minutes </li>
+
−
<li>Protein half-life: 90 minutes</li>
+
−
<li>Plasmid copy number: 1 (i.e. stable integration into the genome) or 20</li>
+
−
<li>Cre delivery method: as individual protein; or as plasmid expressing Cre recombinase</li>
+
−
<li>For plasmid expressing Cre: </li>
+
−
<ul class="inner-model">
+
−
<li> Transcription rate: 1 mRNA molecule per 100 seconds </li>
+
−
<li> Translation rate: adjusted so that the burst factor is 2 </li>
+
−
</ul>
+
−
<li>For delivery of individual Cre protein:
+
−
<ul class="inner-model">
+
−
<li> Simulation performed with delivering 100, 1000, and 10000 Cre molecules </li>
+
−
</ul>
+
−
</li>
+
−
</ul>
+
−
<br>
+
−
<p>
+
−
Guide:
+
−
</p>
+
−
<ul class= "model-ul">
+
−
<li>PC2 = Recombination Product with two Cre protein molecules attach to it (Cre binds to target site with very high affinity, so with a low protein degradation rate, Cre stably associate with the target site in the product construct). </li>
+
−
<li>Simulations are repeated for 2000 times and are shown as an average value with +/- 1 standard deviation.</li>
+
−
</ul>
+
−
<br>
+
−
<p>
+
−
Results:
+
−
</p>
+
−
<br>
+
−
+
−
<p style="text-align:center;">
+
−
Delivery of 100 Cre Proteins: Genome integration (Figure 2) and Transient expression (figure 3):
+
−
</p>
+
−
<br>
+
−
+
−
</div>
+
−
</div>
+
 
 
−
<div class="row">
+
<div class="col-md-offset-1 col-md-3 bottom-column">
−
<div class="col-md-6">
+
<a href="https://2017.igem.org/Team:TECHNION-ISRAEL/ModelCRE">
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/a/af/T--TECHNION-ISRAEL--model1.png" alt = "">
+
<img src="https://static.igem.org/mediawiki/2017/4/46/T--TECHNION-ISRAEL--model_intro_1.png" class="no-rad" alt=""  style= "width:40%; margin: auto;">
−
+
</a>
−
<p style="text-align:center;"> <strong> Figure 2 </strong> </p>
+
</div>
−
</div>
+
</div>
−
+
</div>
−
<div class="col-md-6">
+
</div>
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/4/4e/T--TECHNION-ISRAEL--model2.png" alt = "">
+
−
+
<br>
−
<p style="text-align:center;"> <strong> Figure 3 </strong> </p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
<br>
+
−
<br>
+
−
+
−
<div class="row">
+
−
<div class="col-md-12">
+
−
<p style="text-align:center;">
+
−
Delivery of 1000 Cre Proteins: Genome integration (figure 4) and Transient expression (Figure 5):
+
−
</p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
+
−
<div class="row">
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/0/0c/T--TECHNION-ISRAEL--model3.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 4 </strong> </p>
+
−
</div>
+
−
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/9/9e/T--TECHNION-ISRAEL--model4.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 5 </strong> </p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
<br>
+
−
<br>
+
−
+
−
<div class="row">
+
−
<div class="col-md-12">
+
−
<p style="text-align:center;">
+
−
Delivery of 1 Cre expressing plasmid: Genome integration (Figure 6) and Transient expression (Figure 7)
+
−
</p>
+
−
</div>
+
−
</div>
+
−
+
−
<br>
+
−
<div class="row">
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/d/d6/T--TECHNION-ISRAEL--model5.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 6 </strong> </p>
+
−
</div>
+
−
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/0/0b/T--TECHNION-ISRAEL--model6.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 7 </strong> </p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
<br>
+
−
<br>
+
−
+
−
<div class="row">
+
−
<div class="col-md-12">
+
−
<p style="text-align:center;">
+
−
Delivery of 5 Cre expressing plasmid: Genome integration (Figure 8) and Transient expression (Figure 9)
+
−
</p>
+
−
</div>
+
−
</div>
+
−
+
−
<br>
+
−
<div class="row">
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/9/9f/T--TECHNION-ISRAEL--model7.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 8 </strong> </p>
+
−
</div>
+
−
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/3/33/T--TECHNION-ISRAEL--model8.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 9 </strong> </p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
<br>
+
−
<br>
+
−
+
−
<div class="row">
+
−
<div class="col-md-12">
+
−
<p style="text-align:center;">
+
−
Delivery of 10 Cre expressing plasmid: Genome integration (Figure 10) and Transient expression (Figure 11)
+
−
</p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
<div class="row">
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/8/86/T--TECHNION-ISRAEL--model9.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 10 </strong> </p>
+
−
</div>
+
−
+
−
<div class="col-md-6">
+
−
<img class= "modelimg" src= "https://static.igem.org/mediawiki/2017/2/2c/T--TECHNION-ISRAEL--model10.png" alt = "">
+
−
+
−
<p style="text-align:center;"> <strong> Figure 11 </strong> </p>
+
−
</div>
+
−
</div>
+
−
<br>
+
−
<br>
+
−
<div class="row">
+
−
<div class="col-md-12">
+
  
−
<p>
+
</div>
−
Analysis:
+
</div>
−
</p>
+
</div>
−
+
</div>
−
<p>
+
−
Based on the modelling results and clinical consideration we decided to forgo using Cre recombinases for our “Kill Switch”. As can be seen in Figure 6, the Cre recombinase at times is incapable of achieving the 100% recombination we require. It is our understanding that any recombination based system may ever fully eliminate every copy of our plasmid, and as such we decided to focus on a “Suicide Mechanism” wherein every cell containing our plasmid will undergo apoptosis. This is both more effective for our purposes and clinically proven.  
+
<a id="back-to-top" href="#" class="btn btn-lg back-to-top" role="button"><img src="https://static.igem.org/mediawiki/2017/f/f9/T--TECHNION-ISRAEL--newUpAB.png" alt=""></a>
−
</p>
+
−
<br>
+
  
−
<p>
 
−
Lastly, we would like to thank team SMORE again for the amazing work they did, our project would not have been the same without their help. 
 
−
</p>
 
−
 
−
</div>
 
−
 
−
</div>
 
−
</div>
 
−
 
−
</div>
 
−
</div>
 
−
 
−
<a id="back-to-top" href="#" class="btn btn-lg back-to-top" role="button" title="Up" data-toggle="tooltip" data-placement="left"><img src="https://static.igem.org/mediawiki/2016/5/5a/T--Technion_Israel--up_arrow.png" alt=""></a>
 
  
 
</body>
 
</body>
 
</html>
 
</html>
 
{{:Team:TECHNION-ISRAEL/sponsors}}
 
{{:Team:TECHNION-ISRAEL/sponsors}}

Latest revision as of 02:23, 2 November 2017

navbar

Model

Model





Modelling is an important part of any project within iGEM. As part of our project, we decided to model two separate systems: We created a kinetic model for the Tolerance Assay Model, and collaborated with team Edinburgh UG in order to model a potential “Kill Switch.”
Each of these models provided us with important information that directly impacted our general design and our wet-lab experiments.




My First Website

Department of Biotechnology & Food Engineering
Technion – Israel Institute of Technology
Haifa 32000, Israel

    • igem.technion.2017@gmail.com